What are the perioperative concerns for a patient with rheumatic heart disease who has severe tricuspid regurgitation and moderate mitral regurgitation?

Perioperative Concerns for RHD with Severe TR and Moderate MR

This patient requires concomitant tricuspid valve repair at the time of mitral valve surgery, as severe TR will not predictably improve after isolated mitral intervention and reoperation for TR carries 10-25% mortality. 1

Critical Surgical Decision

The 2014 AHA/ACC guidelines provide a Class I recommendation that tricuspid valve surgery is indicated for patients with severe TR undergoing left-sided valve surgery 1. This is non-negotiable. The evidence is clear that:

• Severe TR (whether primary or functional) does not reliably improve after correction of left-sided lesions alone
• Reoperation for isolated TR after mitral surgery has perioperative mortality of 10-25% 1
• Tricuspid repair adds minimal operative risk and only clinically insignificant increases in ischemic time 1
• Repair is strongly preferred over replacement 1

Key Hemodynamic Concerns

Right Ventricular Function Assessment

The most critical perioperative predictor is RV systolic function 1. You must determine:

• Severe RV dysfunction = relative contraindication to surgery due to risk of postoperative RV failure 1
• Progressive RV dilation on serial imaging = worsening prognosis
• RV function determines surgical outcomes more than any other factor 1

Pulmonary Hypertension Evaluation

Assess pulmonary artery systolic pressure (sPAP):

• sPAP >73.5 mmHg = significantly increased surgical mortality (RR 1.04 per mmHg increase) 2
• Irreversible pulmonary hypertension = relative contraindication to surgery 1
• Severe pulmonary hypertension with severe TR may have similar outcomes whether or not TR is repaired 3, though guidelines still recommend repair 1

Preoperative Optimization

Volume Status Management

Diuretics are Class IIa for symptomatic severe TR 1:

• Loop diuretics for peripheral edema and ascites
• Caution: Can worsen low-flow syndrome
• Add aldosterone antagonists for hepatic congestion (promotes secondary hyperaldosteronism) 1

Atrial Fibrillation

AF is a significant risk factor for:

• Progression of TR 1, 4
• Worse postoperative outcomes 4
• Must be addressed perioperatively

Assess for End-Organ Damage

Look for signs of:

• Hepatic congestion (elevated liver enzymes, coagulopathy)
• Renal dysfunction
• These indicate advanced disease and higher surgical risk 5

Intraoperative Management Priorities

Hemodynamic Goals

For severe TR with moderate MR:

1. Maintain preload: These patients are preload-dependent
2. Avoid bradycardia: Maintain adequate heart rate to optimize cardiac output
3. Minimize RV afterload: Avoid hypoxia, hypercarbia, acidosis (all increase pulmonary vascular resistance)
4. Consider invasive monitoring: Arterial line, central venous pressure, possibly PA catheter or TEE 6

Anesthetic Considerations

• Avoid agents that significantly increase pulmonary vascular resistance
• Maintain contractility (RV is already compromised)
• Have inotropic support readily available
• Consider pulmonary vasodilators if pulmonary hypertension is severe 1

Specific Surgical Approach

For the Tricuspid Valve

Rigid ring annuloplasty is preferred 7:

• Assess annular dilation (>40 mm or >21 mm/m² on TTE; >70 mm on direct intraoperative measurement) 1
• Repair is superior to replacement 1
• If replacement necessary: individualize prosthesis choice (mechanical vs. bioprosthetic) 1
• Large bioprostheses currently favored over mechanical valves 8

For the Mitral Valve

• Address the rheumatic mitral pathology (likely replacement given rheumatic etiology) 1
• Perioperative mortality is higher for combined mitral + tricuspid surgery vs. isolated procedures, but this is acceptable given the alternative of reoperation 1

Postoperative Concerns

Immediate Risks

• RV failure: Most concerning complication
• Low cardiac output syndrome (higher risk if TR not repaired) 9
• Arrhythmias (especially with concomitant AF)
• Prolonged ventilation requirements

Follow-up Monitoring

• Serial echocardiography to assess:
  • Residual TR (should be mild or less)
  • RV function recovery
  • Pulmonary pressures
• Monitor for heart failure symptoms
• Risk of rehospitalization for CHF is significantly lower with TR repair 9

Critical Pitfalls to Avoid

1. Do NOT defer tricuspid repair thinking it will improve after mitral surgery alone—it won't 1
2. Do NOT underestimate RV dysfunction—it's the primary determinant of surgical mortality 1
3. Do NOT operate if severe, irreversible pulmonary hypertension or severe RV dysfunction present—mortality is prohibitive 1
4. Do NOT use aggressive diuresis preoperatively—can precipitate low-flow syndrome 1

Evidence Quality Note

The recommendations are primarily Level C evidence (expert consensus), as randomized trials in this population are lacking 1. However, the consistency across multiple international guidelines (AHA/ACC, ESC/EACTS) 1, 10, 8 and supporting observational data 2, 9, 3 provide strong support for concomitant tricuspid repair.